

## Info Sheet for Technical description

No. 0001

### Organization

\* Mandatoty fields

|  |  |  |
|--|--|--|
| Name of Organization*                                      | Cyfuse Biomedical K.K.   |  |
| Address, City, States, Zip, Country*                       | West Wing-1F, Sumitomo Fudosan Mita Twin Bldg. 3-5-27, Mita, Minato-ku, Tokyo  |  |
| URL  | <a href="http://www.cyfusebio.com">www.cyfusebio.com</a>   |  |
| Brief Descriptions of Organization*<br>(Approx. 100 words) | <p>Since its establishment in 2010, Cyfuse has been in business with the mission of making social contributions in the medical field, including regenerative medicine and drug discovery, by fabricating three-dimensional tissues and organs composed of "only cells."</p> <p>One of the goals of Cyfuse has been made to ensure that steric constructs created with the use of spheroids obtained via the phenomenon of cell aggregation and Bio 3D Printer is put to practical use as cellular products. We are also working on developing this Japanese technology on a global scale as well as becoming a leading company in regenerative medicine.</p> |  |
| Contact address  | Name*  | Toshihiko Maekawa  |
|  | Department* / Position   | Research and Development/General Manager   |
|  | E-mail* / TEL  | <a href="mailto:toshihiko.maekawa@cyfusebm.com">toshihiko.maekawa@cyfusebm.com</a> |

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**

\* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

| Options*                                | Comments   |
|---|--|
| <input checked="" type="checkbox"/> Yes | If FIRM uses the presentation material, FIRM will ask Cyfuse for confirmation. |
| <input type="checkbox"/> No             |  |

Filled in by\*

Date\*

|                   |
|-------------------|
| Toshihiko Maekawa |
| 2023/9/22         |

**Sheet [A]** Clinical Development Pipelines**Info Sheet for Technical overview**

No. 0001

\* Mandatoty fields

**Title\***

Clinical development pipelines

**Development Phase\***

- |   |   |   |
|---|---|---|
| <input type="checkbox"/> Basic Research           | <input type="checkbox"/> Drug Discovery                       | <input type="checkbox"/> Pre-Clinical               |
| <input type="checkbox"/> Clinical Trial (Phase I) | <input checked="" type="checkbox"/> Clinical Trial (Phase II) | <input type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review                   | <input type="checkbox"/> Others                               |   |

**Disease Area\***

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> Cancer          | <input type="checkbox"/> Central nervous system | <input type="checkbox"/> Ophthalmology     |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism | <input type="checkbox"/> Cardiovascular    |
| <input type="checkbox"/> Urogenital      | <input type="checkbox"/> Digestive organ        | <input checked="" type="checkbox"/> Blood  |
| <input type="checkbox"/> Infection       | <input type="checkbox"/> Dermatology            | <input type="checkbox"/> Immunity          |
| <input type="checkbox"/> Otolaryngology  | <input type="checkbox"/> Respiratory            | <input checked="" type="checkbox"/> Others |

**Description\***

We have three pipelines of regenerative medicine products in the clinical trial stage..

- Nerve regeneration  
Cellular nerve conduit for traumatic peripheral nerve injury.
- Vascular regeneration  
Development of cellular artificial blood vessels for shunts for dialysis patients with severe renal failure.
- Bone and cartilage regeneration  
Development of new regenerative medicine products that regenerate bone and cartilage simultaneously.

**Filled in by\***

Toshihiko Maekawa

**Date\***

2023/9/22